hydroxychloroquine has been researched along with Death, Sudden, Cardiac in 9 studies
Hydroxychloroquine: A chemotherapeutic agent that acts against erythrocytic forms of malarial parasites. Hydroxychloroquine appears to concentrate in food vacuoles of affected protozoa. It inhibits plasmodial heme polymerase. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p970)
hydroxychloroquine : An aminoquinoline that is chloroquine in which one of the N-ethyl groups is hydroxylated at position 2. An antimalarial with properties similar to chloroquine that acts against erythrocytic forms of malarial parasites, it is mainly used as the sulfate salt for the treatment of lupus erythematosus, rheumatoid arthritis, and light-sensitive skin eruptions.
Death, Sudden, Cardiac: Unexpected rapid natural death due to cardiovascular collapse within one hour of initial symptoms. It is usually caused by the worsening of existing heart diseases. The sudden onset of symptoms, such as CHEST PAIN and CARDIAC ARRHYTHMIAS, particularly VENTRICULAR TACHYCARDIA, can lead to the loss of consciousness and cardiac arrest followed by biological death. (from Braunwald's Heart Disease: A Textbook of Cardiovascular Medicine, 7th ed., 2005)
| Excerpt | Relevance | Reference |
|---|---|---|
| "HCQ is a potential cause of sudden cardiac death in COVID-19 patients." | 6.72 | COVID-19, hydroxychloroquine and sudden cardiac death: implications for clinical practice in patients with rheumatic diseases. ( Agarwal, V; Gupta, L; Raza, HA; Tariq, J, 2021) |
| "Using the O'Hara-Rudy computer model of human ventricular wedge, we evaluate the arrhythmogenic potential of clinical factors that can further alter repolarization in COVID-19 patients in addition to hydroxychloroquine (HCQ) and azithromycin (AZM) such as tachycardia, hypokalaemia, and subclinical to mild long QT syndrome." | 4.02 | Modelling sudden cardiac death risks factors in patients with coronavirus disease of 2019: the hydroxychloroquine and azithromycin case. ( Baró, I; Charpentier, F; De Waard, M; Loussouarn, G; Montnach, J, 2021) |
| "The incidence and nature of arrhythmias in the setting of COVID-19 were poorly documented across studies." | 2.72 | Incidence and treatment of arrhythmias secondary to coronavirus infection in humans: A systematic review. ( Amarasekera, AT; Kayes, T; Kodsi, M; MacIntyre, CR; Malaty, M; Tan, TC, 2021) |
| "HCQ is a potential cause of sudden cardiac death in COVID-19 patients." | 2.72 | COVID-19, hydroxychloroquine and sudden cardiac death: implications for clinical practice in patients with rheumatic diseases. ( Agarwal, V; Gupta, L; Raza, HA; Tariq, J, 2021) |
| " The association was stronger among current-high daily dosage [15." | 1.72 | QTc-interval prolongation and increased risk of sudden cardiac death associated with hydroxychloroquine. ( Ahmadizar, F; Ikram, MA; Kavousi, M; Kors, JA; Soroush, N; Stricker, BH, 2022) |
| "Hydroxychloroquine (HQ) has been used for the treatment of novel coronavirus disease (COVID-19) even though there is no clear evidence for its effectiveness yet." | 1.62 | Sudden Cardiac Death in Haemodialysis Patients under Hydroxychloroquine Treatment for COVID-19: A Report of Two Cases. ( Dincer, MT; Karaca, C; Murt, A, 2021) |
| " For the lack of efficacy, we discuss the fundamental differences of treatment initiation between in vitro and in vivo studies, the pitfalls of the pharmacological calculations of effective blood drug concentrations and related dosing regimens, and the possible negative effect of HCQ on the antiviral type-I interferon response." | 1.56 | It is time to drop hydroxychloroquine from our COVID-19 armamentarium. ( Kashour, T; Tleyjeh, IM, 2020) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 9 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Giudicessi, JR | 1 |
| Noseworthy, PA | 1 |
| Friedman, PA | 1 |
| Ackerman, MJ | 1 |
| Cipriani, A | 1 |
| Zorzi, A | 1 |
| Ceccato, D | 1 |
| Capone, F | 1 |
| Parolin, M | 1 |
| Donato, F | 1 |
| Fioretto, P | 1 |
| Pesavento, R | 1 |
| Previato, L | 1 |
| Maffei, P | 1 |
| Saller, A | 1 |
| Avogaro, A | 1 |
| Sarais, C | 1 |
| Gregori, D | 1 |
| Iliceto, S | 1 |
| Vettor, R | 1 |
| Murt, A | 1 |
| Dincer, MT | 1 |
| Karaca, C | 1 |
| Malaty, M | 1 |
| Kayes, T | 1 |
| Amarasekera, AT | 1 |
| Kodsi, M | 1 |
| MacIntyre, CR | 1 |
| Tan, TC | 1 |
| Kashour, T | 1 |
| Tleyjeh, IM | 1 |
| Raza, HA | 1 |
| Tariq, J | 1 |
| Agarwal, V | 1 |
| Gupta, L | 1 |
| Ahmadizar, F | 1 |
| Soroush, N | 1 |
| Ikram, MA | 1 |
| Kors, JA | 1 |
| Kavousi, M | 1 |
| Stricker, BH | 1 |
| Wiwanitkti, V | 1 |
| Montnach, J | 1 |
| Baró, I | 1 |
| Charpentier, F | 1 |
| De Waard, M | 1 |
| Loussouarn, G | 1 |
2 reviews available for hydroxychloroquine and Death, Sudden, Cardiac
| Article | Year |
|---|---|
Incidence and treatment of arrhythmias secondary to coronavirus infection in humans: A systematic review.
Topics: Anti-Arrhythmia Agents; Anti-Bacterial Agents; Antimalarials; Arrhythmias, Cardiac; Atrial Fibrillat | 2021 |
COVID-19, hydroxychloroquine and sudden cardiac death: implications for clinical practice in patients with rheumatic diseases.
Topics: Antirheumatic Agents; COVID-19; COVID-19 Drug Treatment; Death, Sudden, Cardiac; Humans; Hydroxychlo | 2021 |
7 other studies available for hydroxychloroquine and Death, Sudden, Cardiac
| Article | Year |
|---|---|
Urgent Guidance for Navigating and Circumventing the QTc-Prolonging and Torsadogenic Potential of Possible Pharmacotherapies for Coronavirus Disease 19 (COVID-19).
Topics: Anti-Infective Agents; Betacoronavirus; Coronavirus Infections; COVID-19; Death, Sudden, Cardiac; Dr | 2020 |
Arrhythmic profile and 24-hour QT interval variability in COVID-19 patients treated with hydroxychloroquine and azithromycin.
Topics: Antiviral Agents; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; Death, Sudden, Ca | 2020 |
Sudden Cardiac Death in Haemodialysis Patients under Hydroxychloroquine Treatment for COVID-19: A Report of Two Cases.
Topics: Aged; Aged, 80 and over; Azithromycin; COVID-19; COVID-19 Drug Treatment; Death, Sudden, Cardiac; Dr | 2021 |
It is time to drop hydroxychloroquine from our COVID-19 armamentarium.
Topics: Animals; Antiviral Agents; Arrhythmias, Cardiac; Azithromycin; Bradycardia; COVID-19 Drug Treatment; | 2020 |
QTc-interval prolongation and increased risk of sudden cardiac death associated with hydroxychloroquine.
Topics: Aged; COVID-19 Drug Treatment; Death, Sudden, Cardiac; Electrocardiography; Female; Follow-Up Studie | 2022 |
Sudden Cardiac Death, Haemodialysis, Hydroxychloroquine, and COVID-19.
Topics: COVID-19 Drug Treatment; Death, Sudden, Cardiac; Humans; Hydroxychloroquine; Renal Dialysis; SARS-Co | 2022 |
Modelling sudden cardiac death risks factors in patients with coronavirus disease of 2019: the hydroxychloroquine and azithromycin case.
Topics: Azithromycin; COVID-19 Drug Treatment; Death, Sudden, Cardiac; Humans; Hydroxychloroquine; Long QT S | 2021 |